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ameliorate the disease sequelae in evidently infected fetus-
es (therapeutic use), as demonstrated by the regression or 
even resolution of sonographic pathologies including pla-
cental inflammation.  © 2015 S. Karger AG, Basel 
 Epidemiology of Cytomegalovirus Infection in 
Pregnancy and Preventive Measures 
 Human cytomegalovirus (CMV) is a double-stranded, 
enveloped DNA virus belonging to the betaherpesvirus 
subfamily. After coming into contact with CMV contain-
ing body fluids such as blood, saliva, urine, breast milk or 
genital secretions, the virus invades mucosal surfaces and 
replicates in permissive cells (myeloic cells, hepatocytes, 
lung fibroblasts, endothelia, cytotrophoblast, neuronal 
precursor cells, etc.)  [1–5] . After repeated waves of viremia, 
the virus establishes lifelong latency in myeloic cells  [1, 2] . 
However, reactivation of latent CMV or reinfection with a 
different CMV strain, accompanied by periodic episodes of 
viral shedding via bodily fluids, can occur in seropositive 
individuals  [2] . While primary CMV infection in immuno-
competent individuals is mostly asymptomatic or mani-
fests itself as a mild flu-like syndrome, CMV infection in 
immunocompromised subjects or fetuses results in a seri-
ous, sometimes even life-threatening complication  [6] .
 Depending on the population (industrialized vs. de-
veloping regions) and social status, around 10–50% of 
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 Abstract 
 Primary infection with the human cytomegalovirus (CMV) 
occurs in 1–4% of pregnancies. The rates of maternal-fetal 
CMV transmissions are around 25, 36, 41, and 66%, for infec-
tions occurring in the peri-conceptional weeks, first, second, 
and third trimester of pregnancy, respectively. On the other 
hand, the severity of fetal organ damage and dysfunction 
diminishes with increasing gestational age. Congenitally 
CMV-infected newborns may have neurosensory impair-
ments like mental retardation, cerebral palsy, epilepsy, pro-
gressive hearing loss or visual defects, or even may have a 
fatal outcome. In in-vitro experiments, CMV specific neutral-
izing IgG antibodies – which are abundant in CMV specific 
hyperimmune globulin (HIG) products – inhibited the entry 
of the virus into target cells and hampered viral cell-to-cell 
spread. This article provides a brief overview on the epide-
miology and diagnostic tools in congenital CMV infection. It 
also concisely summarizes the currently available study re-
sults on the safety and effectiveness of HIG treatment. Ac-
cordingly, in clinical studies HIG administration to expectant 
mothers following primary CMV infection (prophylactic use) 
was shown to lower the risk of maternal-fetal transmission of 
CMV compared to untreated controls. HIG was also able to 
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women at childbearing age are seronegative for CMV, 
and 1–4% of them contract primary infection during 
pregnancy. Vertical transmission rates of 30–50% were 
reported  [7–12] . 
 The global prevalence of congenital CMV infection 
in  newborns is 0.64%  [9] . At birth, approximately 10–
25% of congenitally CMV-infected newborns present 
with clinical signs such as jaundice, petechiae, hepato-
splenomegaly, microcephaly, and cerebral cortical mal-
formations  [8] . In general, symptomatic newborns have 
an unfavorable prognosis: approximately, 5–15% die 
within the first 6 weeks of life, and 40–60% typically suffer 
from mental retardation, cerebral palsy, epilepsy, pro-
gressive hearing loss or visual defects, resulting in perma-
nent disabilities  [6, 8, 13, 14] . As miscarriages are seldom 
recognized as a consequence of primary CMV infection, 
the true number of affected infants is estimated to be even 
higher than what reports from literature suggest. How-
ever, also 10–15% of infants asymptomatic at birth may 
develop long-term sequelae later in life  [8, 15] . In fact, 
more children suffer from permanent disabilities due to 
congenital CMV infection than due to diseases of higher 
public awareness such as Down syndrome, fetal alcohol 
syndrome, or neural tube defects  [15] . 
 Hygienic measures constitute an effective way to low-
er the rate of primary CMV infection in pregnant women 
 [16–18] . As latently infected young infants may shed 
CMV in urine or saliva over years, they represent the 
most common source of expectant mothers’ infection  [2, 
19] . Therefore, the Center for Disease Control and Pre-
vention (CDC) recommends to seronegative pregnant 
women very simple and manageable hygienic precaution 
measures like frequent hand washing after contact with 
body fluids of a child who’s CMV status is positive or un-
known, and avoidance of too intimate contact with such 
a child (i.e. kisses on the mouth, sharing food, drink or 
flatware), to reduce their risk of infection. However, ac-
cording to surveys conducted in the United States be-
tween 2005 and 2007, only 14–22% of female respondents 
out of the general population ever had heard of CMV 
 [20, 21] , and only about a half of obstetricians and gyne-
cologists routinely counseled their patients about CMV 
and infection-prevention measures  [20, 22] .
 Pathophysiology of Intrauterine CMV Infection 
 CMV replicates in uterine glandular epithelium and 
capillary endothelial cells and spreads to cytotrophoblasts 
and vasculature in the villous core  [23–25] . Recent obser-
vations suggest that the virus utilizes the fetal Fc-receptor 
for its transfer across the decidual-placental interface. 
The physiological role of the neonatal Fc-receptor is to 
actively transport IgG from the intervillous space (mater-
nal blood flow) to the syncytiotrophoblast  [26, 27] . Both, 
the expression of this receptor and the IgG transfer in-
crease with gestational age  [27, 28] . This might explain 
why vertical transmission rates, as well as potentially pro-
tective maternal IgG antibodies in the fetal bloodstream 
are higher in the late gestation as compared to the first or 
second trimester  [29, 30] . Indeed, the transmission rates 
among studies are remarkably consistent ranging from 
30–42%, 38–44%, and 59–73% for the first, second, and 
third trimester, respectively  [10, 12, 30, 31] . For infections 
in the pre-conceptional (3–12 weeks before conception) 
and peri-conceptional (less than 3 weeks before concep-
tion to the time after conception) period, the risk of CMV 
transmission is approximately 6–9% and 19–31%, respec-
tively  [30, 32–34] . Infections during early pregnancy 
bear the highest risk of severe sequelae in the offspring 
 [12, 33, 35, 36] . The clinical signs observed in CMV in-
fected fetuses and newborns are likely to be associated 
with the cytopathic effects of the virus, inflammatory re-
actions secondary to viral replication, or the consequenc-
es of placental dysfunction  [37–40] .
 Diagnosis of Primary Maternal and Fetal CMV 
Infection and Prognostic Factors 
 Recent primary maternal CMV infection is diagnosed 
by the detection of CMV-specific IgM and low-avidity 
IgG in serum of a previously seronegative subject (sero-
conversion)  [41, 42] . A detectable antibody response usu-
ally appears at about 2–12 weeks after virus contact  [41, 
43] . Sonographic signs such as an increase in placental 
vertical diameter, hyperechogenic bowel, hydronephro-
sis, fetal hydrops, hepatomegaly, cerebral periventricular 
echodensities, cerebral ventriculomegaly, microcephalus 
and overall growth retardation are typical and indicative 
signs of materno-fetal CMV transmission  [38, 44, 45] . 
According to Guerra and colleagues, ultrasound exami-
nations do have positive and negative predictive values of 
78 and 48%, respectively, for poor clinical outcome of ev-
idently infected fetuses  [44] . As the placenta is one of the 
fetal structures most heavily affected by intrauterine 
CMV infection  [24] , the increased placental thickness in 
primarily CMV-infected pregnant women has also been 
identified as a prognostic marker (p < 0.0001). The pla-
cental thickening is even more pronounced when accom-





panied by fetal anomalies (p < 0.0001) and should, thus, 
be included in the overall estimate of fetal prognosis  [38] .
 The detection of CMV-DNA via polymerase chain re-
action (PCR) in amniotic fluid samples (>20th week of 
gestation and >6 weeks after presumed maternal infec-
tion) constitute proof of maternal-fetal virus transmission 
 [41, 42] . Contrary to what physicians might anticipate, the 
viral load in the amniotic sac does not seem to be a reliable 
predictor of neonatal clinical outcome  [46, 47] . Further-
more, data on the usefulness of CMV specific IgM and 
CMV-DNA concentrations in fetal umbilical cord blood 
as prognostic parameters are conflicting  [41, 48, 49] .
 In the newborn, it is recommended to perform PCR 
for CMV-DNA in urine or saliva in the first two postnatal 
weeks. This approach helps to discriminate between con-
genital infection and perinatal infection (from cervical 
 secretions, breast feeding or blood products)  [41, 42] . In-
formation from umbilical cord blood collected after de-
livery is regarded as less reliable, because blood may be 
heavily contaminated with maternal cells  [50] . Less fre-
quently or not routinely employed diagnostic methods 
include the detection of viral antigens (e.g. pp65) or virus-
specific RNA in blood, rapid virus culture and immuno-
histochemistry  [41] . 
 The premature termination of pregnancy is still the 
‘only option’ frequently offered to parents who are not 
willing to give birth to a severely disabled neonate in case 
of documented fetal CMV infection combined with sono-
graphically confirmed anomalies in the fetus  [41] . How-
ever, premature termination at this stage of pregnancy 
may be subject to legal restrictions and may give rise to 
ethical objections; this is because of the fact that the sever-
ity of the neonate’s deficits is difficult to predict  [41, 51, 
52] . Facing this social and ethical dilemma, health care 
professionals increasingly recognize anti-CMV specific 
hyperimmune globulin preparations (HIG) – though 
currently not approved for this indication – as a treat-
ment option that is worth considering. 
 Mechanism of Action of CMV-Specific Hyperimmune 
Globulin 
 Circumstantial scientific evidence supports the con-
cept of protecting fetuses from vertical CMV transmission 
and severe CMV-related sequelae by the administration of 
HIG. In detail, the maternal-fetal CMV transmission rate 
is considerably lower in pregnant women with preexisting 
humoral immunity (CMV reactivation or reinfection) 
than in women experiencing primary CMV infection (1.4 
vs. 30–50%), respectively  [9] . Likewise, CMV-related se-
quelae in corresponding newborns are milder or even ab-
sent  [19, 53] , although hearing deficits were reported to 
occur at a similar rate  [54] . Moreover, the plasma titers of 
CMV-specific neutralizing IgG with high avidity are in-
versely correlated with virus transmission rates and with 
CMV associated histopathological findings in placenta 
tissue  [25, 26, 42, 55] . The observation that neonatal clin-
ical manifestations and sequelae of CMV infection run a 
much milder course, if the maternal infection occurs in 
the late second or third trimester of pregnancy (when the 
trans-placental antibody transfer is already well devel-
oped), fits the concept  [27, 28, 31, 33, 35, 36] . 
 The results of recent in-vitro experiments emphasize 
that the abrogation of virus infectivity by specific neutral-
izing IgG is accomplished through the process of binding 
to viral envelope glycoproteins that is crucial for entry 
into the target cells  [56, 57] . Commercially available im-
mune globulin formulations manufactured from plasma 
of selected donors with high anti-CMV antibody titers 
(anti-CMV hyperimmune globulin; HIG) have a high 
neutralizing capacity  [58] . In addition, HIG was reported 
to exert modulatory activities on the complement system, 
cytokine milieu, expression of Fc receptors, and lympho-
cyte activation  [59–61] . These effects are thought to mit-
igate inflammatory tissue damage in response to the rep-
lication of CMV in fetal organs, as suggested by studies 
on murine brains and human placental tissue  [40, 62] .
 In human clinical studies, HIG treatment was evalu-
ated either for its effectiveness in the prophylaxis of ma-
ternal-fetal transmission of CMV or for its therapeutic 
effect on the severity of manifestations and complications 
in already infected fetuses. 
 HIG for the Prophylaxis of Maternal-Fetal CMV 
Transmission 
 In  table 1 , all studies currently available in literature on 
the prophylactic action of HIG in women primarily in-
fected with CMV during pregnancy are summarized. 
Based on the half-life of IgG of about 22 days  [63] , HIG 
was offered as monthly infusions of 100–200 Paul Ehrlich 
Institute Units (PEIU; units based on the reference stan-
dard of the German Federal Institute for Vaccines and 
Biomedicines) per kilogram maternal body weight  [46, 64, 
65] . In one prospective study  [46] , this treatment reduced 
the rate of fetal CMV infection from 40 to 16% as com-
pared to a control group receiving standard prenatal care 






retrospectively collected data on prophylactic HIG treat-
ment and found the overall proportion of congenitally in-
fected newborns to be 24%, which was lower than what 
authors had expected from their standard of care collec-
tive. Only 2/15 (13%) and 4/14 (29%) women diagnosed 
with primary CMV infection in the first and second tri-
mester, respectively, gave birth to infected newborns, 
compared to the transmission rates of 30–42% and 38–
44%, respectively, in literature  [10, 12, 30, 31] . The rate of 
22% (2/9) of infected newborns born by mothers after 
periconceptional CMV infection was in line with the rate 
of 19–31% previously reported for this subset  [32, 33] . 
However, a historical control group from the same study 
center was not included in this analysis. Another investi-
gation, designed as a randomized, placebo-controlled, 
double-blinded study  [65] comparing monthly infusions 
of HIG versus placebo was recently published and showed 
a trend in favor of prophylactic HIG treatment. The differ-
ence between groups, however, did not reach statistical 
significance (30 vs. 44%; p = 0.13;  table 1 ). Interestingly, 
none of the 10 infected newborns from HIG-treated moth-
ers, but 3 out of the overall 68 uninfected newborns pre-
sented with hearing deficits. It is worth mentioning that 
in  two prophylaxis studies  [46, 64] , all of the congenitally 
infected children born alive by HIG-treated mothers 
were asymptomatic at birth and at follow-up ( table 1 ).
 However, these clinical studies did not provide infor-
mation on the CMV infection status of the fetus prior to 
the start of HIG administration, and thus HIG treatment 
might have been therapeutic rather than prophylactic in 
distinct cases. Furthermore, the mild and unspecific clin-
ical symptoms of maternal CMV infection, and the large 
variability in the diagnostic window of CMV infection 
detection, make the definition of the appropriate time 
point for the start of prophylactic HIG treatment very 
 difficult.
 Therapeutic Effectiveness of HIG in Congenitally 
Infected Fetuses 
 Clinical Outcome of Congenitally Infected Newborns 
 Since 1999, several case reports have provided circum-
stantial evidence that timely HIG administration to expect-
ant mothers and/or their fetuses is able to reduce the sever-
ity of evidently CMV-associated fetal anomalies  [66–69] . 
Larger case series and clinical trials studying this potential 
therapeutic effect included 12–68 mothers diagnosed with 
fetal CMV infection ( table 2 ). In brief, among four prospec-
tive, controlled studies, one study showed a significantly 
lower rate of newborns with congenital CMV infections 
being symptomatic at birth (3 vs. 50%). Three studies found 
a significantly lower rate of CMV-infected infants present-
ing with sequelae after treatment with HIG as compared to 
standard-of-care control groups (11–13% vs. 43–100%) 
 [46, 70, 71] . In a retrospective, matched case-control study 
Table 1.  Clinical studies having investigated the effect of HIG treatment for the prophylaxis of vertical CMV transmission
Author, year 
[Ref.]





Outcome parameter  Results
HIG g roup control group






2 Percentage of congenitally 
infected live births




















0 Percentage of congenitally 
infected neonates/fetuses






 n = Number of pregnant women with primary CMV infection 
included; prosp. = prospective; retrosp. = retrospective; nrd = 
non-randomized; rd = randomized; db = double-blinded; qX w = 
every X weeks. In all studies, a p value <0.05 versus controls was 
considered statistically significant. a Paul Ehrlich Institute Units 
(units based on the reference standard of the German Federal In-
stitute for Vaccines and Biomedicines). The dose per kg maternal 
bodyweight was given intravenously to the expectant mothers. 
b The term ‘symptomatic’ refers to CMV-related signs and symp-
toms at the end of the follow-up period. c Dosing interval not giv-
en. d Number of newborns of mothers solely treated by intrave-
nous infusion. e A total of 17 induced abortions and 1 spontaneous 
miscarriage in the control group (all not examined for CMV infec-
tion).





by Nigro et al.  [72] , the absence of HIG treatment was the 
only independent predictor for complete or partial hearing 
loss (adjusted odds ratio 10 (95% CI 1.3, 84)). In an uncon-
trolled study performed by a Japanese research group  [73] , 
the therapeutic effect of HIG treatment was less convinc-
ing. In this study, 3/12 (25%) of children at >2 years of age 
had a normal outcome, whereas 9/12 (75%) presented with 
hearing impairment or with development delay (7 new-
borns), or died from respiratory failure within the first 
month of life (2 newborns). It is worth noting that in this 
study, 7/12 of mothers received HIG treatment exclusively 
into the fetal abdominal cavity, which resulted in a rate of 









Outcome parameter  Results
HIG group control 
group
Nigro et al., 
2005 [46]
Prosp., nrd 45 200 q2–6w (plus 
400 i.a. or i.u. in 9 
subjects) 1–3 doses
2 Resolution or regress of fetal 
 sonographic anomalies incl. IUGR 






Buxmann et al., 
2012 [64]
Retrosp. 3 180–220c plus ~500e 
i.a. or i.u. 1–3 doses 
1–3 Percentage of symptomatic 
newborns
0/3d –






1–5 Resolution or regress of fetal 
sonographic anomalies incl. IUGR







Nigro et al., 
2012 [70]
Prosp., nrd 16f 200 q4w
1–3 doses
2–8 Resolution of hyperechogenic 
bowel









Visentin et al., 
2012 [71]
Prosp., nrd 68 200
1 dose
1 Resolution or regress of fetal 
sonographic/MRI anomalies incl. IUGR 










12 ~100–200g q1w 
1–5 doses and/or 
~500–1,800e, g q1w 
2–6 doses i.p. 
2–6 Resolution or regress of fetal 
sonographic anomalies incl. IUGR




incl. 2 neonatal 
deaths
–
 n = Number of pregnant women with primary CMV infection 
included; JCCIIFTSG = Japanese Congenital Cytomegalovirus Infec-
tion Immunoglobulin Fetal Therapy Study Group; prosp. = prospec-
tive; retrosp. = retrospective; nrd = non-randomized; qXw = every X 
weeks; i.p. = intraperitoneally (fetal abdominal cavity); i.a. = in-
traamniotically; i.u. = intraumbilically (via cordocentesis); MRI = 
magnetic resonance imaging; IUGR = intrauterine growth retarda-
tion. In all studies, a p value <0.05 versus controls was considered 
statistically significant. a Paul Ehrlich Institute Units (units based on 
the reference standard of the German Federal Institute for Vaccines 
and Biomedicines). If not otherwise specified, the dose per kg mater-
nal bodyweight was given intravenously to the expectant mothers; 
for occasional fetal treatment, dose per fetal bodyweight is indicated. 
b 8/9 fetuses having been treated via amniocentesis or cordocentesis 
were asymptomatic at birth and follow-up. c Dosing interval not giv-
en. d This study included a fourth women treated solely via amnio-
centesis and cordocentesis who gave birth to a symptomatic new-
born. e A fetal weight of 0.5 kg was assumed to convert the absolute 
dose. f The sample included 3 pregnant women with secondary CMV 
infection (1 in the treatment group – normal outcome of the infant, 
2 in the control group – both infants symptomatic) and 2 women 
with twin pregnancies. g A HIG titer of 1 PEIU per mg product and 
a maternal body weight of 75 kg was assumed to convert the absolute 
dose. h Sole maternal treatment in 1 subject (newborn with unilat-
eral hearing deficit), sole fetal treatment in 7 subjects (1 newborn 
with normal outcome, 5 newborns with sequelae, 1 symptomatic 
newborn died from respiratory failure), combined treatment of 
mother and fetus in 4 mother-fetus pairs (2 newborns normal, 1 
symptomatic newborn died from respiratory failure, 1 newborn with 






6/7 of newborns presenting with unfavorable or fatal out-
come. Thus, although this route of HIG administration 
was previously shown to increase the level of IgG in the fe-
tal plasma compartment  [74] , the risk to benefit assess-
ment of this approach remains to be readdressed  [75] . 
 Regress of Fetal CMV-Related Anomalies 
 Pathologies typical for CMV infection improved con-
siderably or even resolved completely following intrave-
nous HIG treatment of pregnant women, whether or not 
combined with intraperitoneal or intraumbilical treat-
ment of fetuses, as demonstrated by serial ultrasono-
graphic examinations. Fetal growth retardation and/or 
sonographic anomalies frequently observed during CMV 
infection regressed or resolved in a total of 39/54 (72%) of 
fetuses in HIG groups, while such observation was rarely 
made in untreated mother-fetus pairs (8/37 [22%]) ( ta-
ble 2 ). However, the study by Visentin et al.  [71] indicated 
that a single dose of HIG may not be sufficient in this in-
dication ( table 2 ). As CMV-related placental dysfunction 
was suggested to play an important role in the develop-
ment of central nervous malformations typically found 
in fetal CMV disease  [37–40] , La Torre et al. and others 
speculated that the regress of placentitis following HIG 
treatment  [24, 38] is paralleled by an amelioration of neu-
rologic disease manifestations in the newborn  [24, 38, 40] . 
The overall high rates of symptomatically infected new-
borns in the trials presented in  tables 1 and  2 may be due 
to the inclusion of mothers infected during the highly 
 vulnerable phase in the first or second trimester of preg-
nancy  [12, 33, 35, 36] , with overrepresentation of infec-
tions in the first trimester (except for the Japanese study).
 Limitations of the Reviewed Studies 
 Recruitment rates of women showing CMV serocon-
version during pregnancy are relatively low in prospec-
tively performed clinical studies ( table 2 ). Furthermore, 
the direct comparison of the study results should be per-
formed only with caution because HIG dosage, route of 
administration, duration of treatment and the time inter-
val between assumed CMV infection and first HIG ad-
ministration varied considerably among the studies and 
even among subjects within the same study ( tables 1 and 
 2 ). Again, it is important to recall that to date, unspecific 
and low-symptomatic clinical manifestations of infec-
tions – such as observed during CMV infection – do not 
allow for the determination of the true onset of the infec-
tion with satisfying reliability  [6] . However, the early de-
tection of maternal CMV infection is crucial for taking 
effective prophylactic measures in order to avoid vertical 
CMV transmission. The period of follow-up investiga-
tions of the newborn is also of relevance. Investigators 
scheduling neonatal follow-up periods shorter than two 
years might miss the identification of potential motoric 
abnormalities or cognitive impairments which might be-
come obvious later in time  [8, 14] .
 Safety of HIG Administration 
 Since the late 1980s, plasma donors are carefully se-
lected from a large population of potential of volunteers. 
In addition, highly elaborate manufacturing processes 
have been established for plasma-derived pharmaceutical 
products, which practically exclude contamination with 
viruses or prions. Today, these processes include virus 
inactivation and removal steps such as cold-ethanol frac-
tioning, solvent-detergent treatment, incubation at low 
pH, pasteurization, and nanofiltration, all of which, taken 
separately, are demonstrably capable of reducing model 
viruses and prions by several orders of magnitude from 
baseline  [76–78] . 
 Mild and transient untoward effects associated with 
intravenous immune globulin treatment (e.g. low-grade 
fever, nausea, myalgia, flushing, chills, malaise, etc.) typi-
cally occur during the first infusion or 1 to 3 days later. 
Patients experiencing tension headaches during an IVIG 
infusion often have a history of hypertension. The devel-
opment of a localized mild and transient urticarial reac-
tion is also common. Serious complications like aseptic 
meningitis, renal failure, hemolysis, or thromboembolic 
complications are rare and were mainly observed in pa-
tients with predisposing underlying risk factors, after ex-
ceptionally high doses, or after administration of formu-
lations containing tubulotoxic stabilizers (no longer in 
use)  [79–81] . Anaphylactic reactions to intravenous im-
mune globulins are extremely rare and often associated 
with preexisting autoantibodies (e.g. anti-IgA)  [80, 82] . 
Therefore, intravenous HIG application to pregnant 
women is considered a very low-risk procedure. In con-
trast, injection into the amniotic sac, and even more the 
cannulation of the fetal abdominal cavity or the umbilical 
cord occasionally performed in studies ( table 2 ) should be 
restricted to specialized centers  [41, 75] .
 In a majority of study reports and publications, thera-
py with HIG is considered a safe and well-tolerated op-
tion. However, Revello and colleagues  [65] paid particu-
lar attention on to six preterms and two growth-retarded 
uninfected newborns in the treatment group versus none 
in the placebo group. Contradictory results brought a re-





cent retrospective analysis pooling the clinical data of 
358 primarily infected women (164 received HIG). This 
study found that birth weight and gestational age of neo-
nates at delivery were significantly higher following ad-
ministration of monthly multiple doses of HIG to moth-
ers compared to untreated controls (p < 0.02)  [83] .
 Summary and Prospects 
 Congenital CMV infection still constitutes one of the 
predominant causes of severe and permanent disabilities 
in children. Attempts to develop a reliable active CMV 
vaccine have not been successful so far  [84] . Although the 
relevance of congenital CMV infection to public health is 
well known for more than 50 years  [85] , routine CMV 
serology screening programs in expectant mothers are 
not yet established in most countries  [41] . This is because 
no CMV-specific treatment approved or established in 
pregnancy is currently available  [6, 11, 52] . However, the 
studies reviewed in this article point to the assumption 
that HIG might be effective in the prophylaxis of mater-
nal-fetal transmission of CMV, and might help reducing 
CMV-associated pathologies in fetuses. Also, the wide-
spread assessment of the CMV serology status of expect-
ant mothers early after conception might add to disease 
prevention. In particular, it would (a) enable individual-
ized hygiene counseling (primary prevention), (b) in-
crease the understanding and awareness to flu-like symp-
toms in CMV-naïve expectant mothers, and (c) increase 
the knowledge on potential interventions by use of HIG 
for prophylactic or therapeutic purposes  [52] . The devel-
opment of a fast, point-of-care CMV testing method with 
high sensitivity, specificity and reproducibility would 
constitute a tremendous step forward in this regard. 
 Currently available information on the effectiveness 
and safety of HIG therapy of CMV infections during 
pregnancy is very promising, but is based only on small 
clinical studies. More scientific evidence helping health 
care professionals to truly understand the value and clin-
ical relevance of HIG administration for prophylactic and 
therapeutic reasons is expected to derive from the results 
of two currently unpublished, prospective, randomized 
clinical trials testing the safety and efficacy of the prophy-
lactic treatment of CMV infection to expectant mothers 
(European Union Clinical Trials Registry No. 2007–
004692–19; U.S. National Institutes of Health registry for 
clinical trials, ID NCT01376778).
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